Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
"Based on current planning assumptions, the Company expects such funds to be sufficient for its operations into the second half of 2022 when top-line results for the IMerge Phase 3 clinical trial in lower risk MDS and completion of patient enrollment for the planned Phase 3 clinical trial in refractory MF are expected."
Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology
…The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as the evidence of disease-modifying activity from biomarker and bone marrow fibrosis assessments.
Brutales Volumen am Freitag! Durchschnitt sind ~7 Mio. Aktien, gehandelt wurden ~346 Mio. Aktien! Wird das die nächste Orphazyme? Ich glaube es zwar nicht, aber man sollte die Aktie und das Volumen definitiv im Auge behalten in der nächsten Woche.
These financial resources, combined with expected future non-dilutive funding under the current debt facility, are now expected to fund operations through the end of the first quarter of 2023.
“We are pleased with the achievement of 91% of the planned enrollment in IMerge Phase 3 and expect the trial to be fully enrolled in the fourth quarter of 2021. In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023,”
Thread abonnieren
